Description: VG Life Sciences Inc. is a biotechnology company. The Company is engaged in developing transformative therapies to treat drug-resistant cancers, infectious diseases and autoimmune diseases caused by chronic inflammation. The Company operates as a drug discovery and development company researching two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The Company's MDT compounds impede tumor cells' ability to meet their energy requirements, leaving cancer cells vulnerable to cancer-killing agents. Its autoimmune therapy, TPT, eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Its peptides are designed to function in all Major Histocompatibility Complex II (MHC-II) phenotypes. It also has a drug research program in pre-clinical stages, a TPT therapy for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) using VG1177.
Home Page: www.vglifesciences.com
121 Gray Avenue
Santa Barbara,
CA
93101
United States
Phone:
805 879 9000
Officers
| Name | Title |
|---|---|
| Mr. Haig Keledjian | Co-Founder, Chairman, CEO, Pres, VP of R&D, CFO and Sec. |
| Dr. M. Karen Newell-Rogers | Chief Scientist |
| Robert A. Forrester | Corp. Counsel |
| Mr. Robert Berliner | Consultant & Advisory Board Member |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 32.3803 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 1999-11-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |